Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers - Oncodaily
Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers Oncodaily
Non-Hodgkin Lymphoma News
Colonic Diffuse Large B-Cell Lymphoma Presenting as Fecal Peritonitis: A Case Report - Cureus
Colonic Diffuse Large B-Cell Lymphoma Presenting as Fecal Peritonitis: A Case Report Cureus
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma - OncLive
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma OncLive
U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings - AboutLawsuits.com
U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings AboutLawsuits.com
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? - Reuters
What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? Reuters
Genmab lymphoma trial cuts progression risk 60% in phase 3 study - Stock Titan
Genmab lymphoma trial cuts progression risk 60% in phase 3 study Stock Titan
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements - Vera Health
Non-Hodgkin lymphoma: inpatient TLS is uncommon but predictable from high–tumor burden and early lab derangements Vera Health
Bayer scores landmark victory as Supreme Court overturns Roundup verdict - Fierce Pharma
Bayer scores landmark victory as Supreme Court overturns Roundup verdict Fierce Pharma
Legend Biotech Establishes Clinical Proof-of-Concept for - GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for GlobeNewswire
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Expected to Witness Significant Expansion Through 2034, According to DelveInsight - Barchart.com
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Expected to Witness Significant Expansion Through 2034, According to DelveInsight Barchart.com
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma CancerNetwork
Genmab stock rises on positive lymphoma trial results By Investing.com - Investing.com Canada
Genmab stock rises on positive lymphoma trial results By Investing.com Investing.com Canada
Advances in lymphoma treatment therapies and clinical trials - Penn Medicine
Advances in lymphoma treatment therapies and clinical trials Penn Medicine
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma - Oncodaily
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma Oncodaily
Genmab (GMAB) Phase 3 epcoritamab combo cuts DLBCL progression risk - Stock Titan
Genmab (GMAB) Phase 3 epcoritamab combo cuts DLBCL progression risk Stock Titan
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Sunday feature: Rylie McCarron is 9 and recently diagnosed with aggressive Lymphblastic Lymphoma - Sumner NewsCow
Sunday feature: Rylie McCarron is 9 and recently diagnosed with aggressive Lymphblastic Lymphoma Sumner NewsCow
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - GlobeNewswire
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes GlobeNewswire
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus
Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics - Medical Xpress
Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics Medical Xpress
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers
Non-Hodgkin lymphoma: cocaine use disorder signals higher inpatient mortality and infectious complications - Vera Health
Non-Hodgkin lymphoma: cocaine use disorder signals higher inpatient mortality and infectious complications Vera Health
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature
Genmab reports positive phase 3 trial results for lymphoma drug By Investing.com - Investing.com Canada
Genmab reports positive phase 3 trial results for lymphoma drug By Investing.com Investing.com Canada
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive
Legend surges on early data for ‘in vivo’ lymphoma cell therapy BioPharma Dive
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus
Current treatment algorithm: diffuse large B cell lymphoma - Nature
Current treatment algorithm: diffuse large B cell lymphoma Nature
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - The ASCO Post
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma The ASCO Post
Diffuse Large B-Cell Lymphoma of the Ethmoid Sinus With Orbital Invasion: A Case Report - Cureus
Diffuse Large B-Cell Lymphoma of the Ethmoid Sinus With Orbital Invasion: A Case Report Cureus
National Poetry Month: "Non-Hodgkin’s Lymphoma" - The Rumpus
National Poetry Month: "Non-Hodgkin’s Lymphoma" The Rumpus
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers